Continuing Education Activity

Acute disseminated encephalomyelitis (ADEM), also referred to as post-infectious encephalomyelitis, is an acute, rapidly progressive autoimmune process. This condition is characterized by demyelination in the brain and spinal cord as a result of inflammation that occurs in response to a preceding infection or immunization.

This activity reviews the typical clinical features of ADEM and discusses the pathophysiological mechanisms involved in this condition. The epidemiology and etiologies are presented, as well as the important differential diagnoses, especially other brain parenchymal inflammatory disorders. The article stresses the importance of clinical, radiological, and laboratory evaluation and management of ADEM; finally, it highlights the role of the interprofessional team in caring for patients with this condition.

Objectives:

• Identify clinical features suggestive of acute disseminated encephalomyelitis, recognizing encephalopathy, polyfocal central nervous system involvement, and demyelinating lesions on brain magnetic resonance imaging.
• Differentiate acute disseminated encephalomyelitis from other central nervous system disorders, viral encephalitis, and multiple sclerosis, ensuring accurate diagnosis and appropriate management.
• Implement clear communication with patients and their families about acute disseminated encephalomyelitis diagnosis, treatment options, potential complications, and long-term prognosis.
• Collaborate with neurologists, radiologists, and immunologists to confirm acute disseminated encephalomyelitis diagnosis, tailor treatment plans, and ensure comprehensive patient care.

Introduction

Acute disseminated encephalomyelitis (ADEM), or post-infectious encephalomyelitis, is an acute, intense, polyfocal, inflammatory autoimmune disorder affecting the central nervous system (CNS). Children are predominantly affected, yet adult cases are not uncommon. ADEM is characterized by demyelination in the brain and spinal cord, and occasionally the optic nerve, due to inflammation that occurs in response to a preceding infection or immunization.[1][2] The diagnosis is mainly clinical, with typical imaging findings on brain magnetic resonance imaging (MRI). The International Pediatric Multiple Sclerosis Study Group developed the modern diagnostic criteria, defining ADEM as an acute demyelinating syndrome that requires the presence of encephalopathy, polyfocal CNS involvement, and demyelinating lesions on brain MRI.[3]

Etiology

ADEM is predominately considered a post-infectious disease of the CNS. An identifiable infection or immunization has been reported in 50% to 85% of cases.[4][5] Most commonly associated organisms include cytomegalovirus, Epstein-Barr virus, herpes simplex virus, human herpes-virus-6, influenza virus, hepatitis A, human immunodeficiency virus, and mycoplasma pneumonia; though, in the majority of cases, the causative pathogen is not identified. Additional associated bacterial infections include Leptospira, beta-hemolytic streptococci, and Borrelia burgdorferi.[6][7][8] Before the development of immunization programs, ADEM was most commonly associated with measles and an increased incidence associated with rubeola, rubella, mumps, varicella, and smallpox. Today, ADEM is more commonly associated with viral infections of the gastrointestinal or respiratory tracts.

ADEM is seen in adults and children approximately 8 to 21 days following immunization. The rabies vaccine is the most commonly reported vaccine associated with ADEM. Other less commonly associated vaccines include measles, pertussis, tetanus, influenza, hepatitis B, diphtheria, rubella, pneumococcus, varicella, smallpox, human papillomavirus, and poliomyelitis. The frequency of ADEM occurring after vaccination has decreased in recent years, likely related to different methodologies in vaccine production.[9]

Epidemiology

Although considered a rare illness, there is an estimated 0.07 to 0.9 per 100,000 children affected by ADEM each year.[10][11] Most cases occur in children with a median age between 5 and 8 years, with the majority being younger than 10 years and the remainder between the ages of 10 and 20. ADEM has also been documented in adults ages 18 to 82. The disease occurs more commonly in males than females, with a male-to-female ratio of 1.3 to 1, and is seen more often seasonally in the winter and spring or the colder months of the year.

The risk of developing ADEM depends on some factors, including an individual’s genetics, exposure to infectious organisms, immunization exposure, and lighter skin pigmentation. All ethnic groups are susceptible to developing ADEM, which occurs worldwide. In 50% to 85% of cases, ADEM is associated with either a preceding infection or vaccination, and most cases follow a viral or bacterial infection. However, the causative pathogen is not always identified.

Pathophysiology

The exact mechanism of ADEM is not entirely understood; it is thought to result from inflammation triggered by an environmental stimulus (eg, vaccination or infectious disease) in genetically susceptible individuals. ADEM has been further characterized as an autoimmune disorder causing demyelination in the CNS. 

There have been proposals that either a cell-mediated response or antibodies produced in response to an environmental trigger cross-react with myelin autoantigens (eg, myelin basic protein, myelin oligodendrocyte protein, proteolipid protein) in the CNS, resulting in the demyelination characteristically seen in ADEM.[12][13][14] An alternative proposed mechanism suggests that ADEM may arise from heightened vascular permeability and congestion in the CNS, triggered by inflammation and circulating immune complexes following vaccination or infection. Mononuclear infiltration of the CNS vasculature is believed to lead to edema around vessels and, occasionally, hemorrhage, causing damage to neighboring neuronal cells (such as demyelination, necrosis, or gliosis); this underlies the diverse clinical presentations and prognoses observed in individuals with ADEM. The inflammation and increased vascular permeability associated with ADEM have also been proposed as a mechanism by which the breakdown of the blood-brain barrier occurs, allowing infiltration of the CNS by both antigens and inflammatory cells involved in the concomitant cell-mediated immune response.

Histopathology

The most specific histopathology of ADEM is perivenous demyelination with an accumulation of florid inflammatory cells, including lymphocytes, macrophages, and microglial cells. The histopathology differs from other demyelinating disorders, especially multiple sclerosis, which shows confluent demyelination. The pathology is typically bilateral and polyfocal with deep gray matter involvement, including the basal ganglia and thalami and polyfocal white matter involvement. Th1 and Th2 inflammatory cytokines and macrophage- and microglia-related cytokines are all increased in ADEM.[5][15]

History and Physical

ADEM is classically seen following an illness or, less frequently, vaccination with a lag time ranging from a few days up to 60 days, with a mean of 26 days. Although in about 25% of affected individuals, there may not be an apparent preceding event. The onset of ADEM is acute and rapidly progressive within days and is characterized by multifocal neurologic symptoms that require early hospitalization.

Some non-specific, constitutional symptoms associated with ADEM include fever, headache, fatigue, malaise, nausea, and vomiting. Based on the recent IPMSSG criteria, diagnosing ADEM requires a combination of encephalopathy and polyfocal neurological deficits.[5] Encephalopathy encompasses altered mental status, which may involve irritability, confusion, psychosis, somnolence, or coma. Polyfocal neurological deficits include motor and sensory, such as paraparesis and tetraparesis. Patients may also present with brainstem deficits like dysarthria or oculomotor dysfunction or other neurologic abnormalities, including seizures, meningismus, ataxia, aphasia, nystagmus, optic neuritis, urinary retention, elevated intracranial pressure, extrapyramidal signs. Most cases of ADEM are monophasic with 1 single event. The clinical severity may fluctuate within 3 months. If there is another episode of inflammatory demyelination after 3 months, the diagnosis is multiphasic ADEM. 

The International Pediatric Multiple Sclerosis Study Group criteria apply mainly to ADEM diagnosis in children. There are no similar diagnostic criteria in adults. Results from most studies found that adults with ADEM have a worse prognosis.[16][17] Some adults with ADEM may also develop signs of peripheral nervous system involvement, defined by abnormalities on electrodiagnostic testing. Signs and symptoms of peripheral involvement may include paresthesia or anesthesia of the limbs and muscle atrophy. Patients with ADEM presenting with peripheral involvement usually have a worse prognosis and increased risk of relapse compared to those with only CNS involvement.

Evaluation

The imaging modality of choice for evaluating ADEM is MRI. It demonstrates hyperintense lesions on T2-weighted, fluid-attenuated inversion recovery, proton-density, and echo-planar trace diffusion MRI sequences. Lesions are not typically visualized on T1-weighted sequences, though larger lesions may appear as hypointensities. Imaging of ADEM may reveal a single lesion (eg, large or small, confluent or solitary) or multiple lesions throughout the white (eg, periventricular and subcortical) and grey (eg, basal ganglia, thalamus, cortex) matter of the brain. ADEM is most characteristically seen as multiple, widespread, asymmetric lesions bilaterally throughout the brain.[18][19][20] There may be additional infratentorial lesions in the brainstem, cerebellum, and spinal cord, but these rarely present as isolated lesions without an accompanying lesion in the brain. MRI lesions in children involve deep gray matter, including the thalami and basal ganglia, whereas MRI lesions in adults tend to be more periventricular.

ADEM lesions are typically present with indistinct margins on imaging; this may help differentiate these lesions from those seen in multiple sclerosis, which usually have clear-cut margins. During the first demyelinating event, the presence of 2 or more periventricular lesions, the presence of T1 black holes, and the absence of a bilateral lesion pattern are all more compatible with the diagnosis of MS.[21]

ADEM may present with a normal MRI or without any visual evidence of disease, even after multiple scans. In some cases, MRI lesions may appear weeks following the onset of symptoms. Although most MRI lesions resolve within 18 months, repeat imaging is warranted, especially early in the course of the disease, as there may be fluctuations in lesions (eg, new lesions may appear while older lesions resolve) despite the patient potentially remaining asymptomatic.

Although MRI is the imaging modality of choice, a computed tomography (CT) scan may be considered in an urgent setting to rule out any other potentially life-threatening causes of neurological dysfunction. In the case of ADEM, a CT scan is most often unremarkable, especially earlier in the course of the disease. In later stages, ADEM may appear as focal or multifocal regions of white matter damage on CT. Cerebrospinal fluid (CSF) analysis (eg, following a lumbar puncture) may reveal abnormalities in 50% to 80% of patients with ADEM. These findings may include lymphocytic pleocytosis, with a white blood cell count of fewer than 100 cells/mL, and a slightly elevated CSF protein, fewer than 70 mg/dL. More specifically, patients with ADEM are often seen to have an elevated level of CSF myelin basic protein on CSF analysis; this is a sign of demyelination in the CNS. An electroencephalogram on a patient with ADEM may reveal a disturbed sleep pattern and either a focal or generalized slowing of electrical activity.

No specific biomarker or diagnostic test establishes a diagnosis of ADEM. The diagnosis of ADEM should be considered when a patient presents with multifocal neurologic deficits without any prior history of neurologic dysfunction. On brain MRI, 1 or more demyelinating lesions, either supratentorial or infratentorial, support a diagnosis of ADEM. These findings, taken together with a history of infection or immunization and abnormal CSF findings, further support a diagnosis of ADEM but are not necessary to do so.

Anti-MOG antibodies have been recently described in a subgroup of children with ADEM.[22] Their clinical presentation and MRI findings are similar. These patients tend to have more relapsing forms of ADEM. They also have more manifestations of optic neuritis and longitudinally extensive transverse myelitis (LETM). Another group of patients may present more specifically with optic neuritis, LETM, or brainstem syndrome with intractable hiccups or vomiting. These typically have neuromyelitis spectrum disorder with positive aquaporin4 antibodies. These patients tend to have worse prognoses concerning long-term neurological deficits.[23]

Although there are no set diagnostic criteria for ADEM in adults, a diagnosis is made with both encephalopathy and multifocal CNS involvement for children. Fifty percent of children with ADEM have also been found to have an elevated sedimentation rate, increased C-reactive protein, and mild leukocytosis.

Treatment / Management

Supportive care and empiric treatment with intravenous (IV) acyclovir and antibiotics may be initiated in patients presenting with meningeal signs, fever, acute encephalopathy, and signs of inflammation in either the blood or CSF. The first-line acute treatment for ADEM is immunosuppression with high-dose IV glucocorticoids. The standard protocol is methylprednisolone at 30 mg/kg/day IV (maximum 1000 mg/day) for 3 to 5 days, followed by an oral prednisone taper for 4 to 6 weeks. Early discontinuation of steroids may increase the risk of relapse.[24][25] These can be started simultaneously with acyclovir or antibiotics on the initial patient presentation.[26][27] If a patient is not improving or is responding poorly to glucocorticoid treatment, IV immunoglobulin is a good second-line therapy. The dose is 2 g/kg for 2 to 5 days. Plasma exchange with 3 to 7 exchanges, or cyclophosphamide, is used in refractory cases.

Differential Diagnosis

Differential diagnosis for ADEM includes the following:

• Aseptic meningitis and acute viral encephalitis include constitutional symptoms suggestive of an underlying infection, including fever, neck rigidity, and elevated acute phase reactants, including C-reactive protein and erythrocyte sedimentation rate
• The first clinical attack of multiple sclerosis: clinical presentation of multifocal neurological deficits and MRI appearance may be similar to ADEM, with some subtle MRI differences; multiple sclerosis relapse usually does not have features of acute encephalopathy
• Diseases associated with myelin oligodendrocyte glycoprotein antibody disease, MOGAD: check myelin oligodendrocyte glycoprotein (MOG) antibody as part of the evaluation, especially in children [5][28]
• Brain metastasis
• Brucellosis
• Cardioembolic stroke
• Cauda equina and conus medullaris syndrome
• Cavernous sinus syndromes
• CNS complications in human immunodeficiency virus
• Cerebral venous thrombosis
• Churg-Strauss disease

Prognosis

The prognosis of ADEM varies widely depending on the age of the patient, the clinical and MRI findings, and the presence of MOG antibodies. The most severe cases of ADEM are called radiological as acute hemorrhagic encephalitis and acute necrotizing leukoencephalitis. These monophasic cases may have a mortality rate of up to 30%. The antecedent infectious illness also determines the prognosis; when cases of ADEM occurred after measles infections, the prognosis was much worse than other infections. In general, 50% to 80% of patients fully recover after a single episode of ADEM. About 25% of children hospitalized require intensive care admission, with a mortality rate of 1% to 3%. Adults have a higher frequency of intensive care unit admission, longer hospitalization, poorer recovery, and higher mortality. Long-term focal neurological deficits are uncommon, and seizures are rare. Cognitive impairment is reported in up to 56% of children after an ADEM.[24][29][30]

Complications

The severity and areas of involvement in the CNS are significant factors determining ADEM complications. Involvement of the long fiber tracts of the white matter may result in long-term complications of physical disability, including spasticity with varying degrees of weakness of the extremities. Post-ADEM epilepsy is not an uncommon complication in children. Both ADEM relapses and epilepsy are more common among children with MOGAD-associated ADEM.[7] Impaired cognitive function may be children’s most important long-term complication of ADEM. Studies have shown that children between 6 and 15 years had mild cognitive deficits with lower intelligence quotient scores 3.5 to 4 years after ADEM. Patients with the onset of ADEM at an older age also had slower verbal processing.[31] 

Deterrence and Patient Education

Educating people about ADEM is crucial. ADEM is an acute and severe inflammation affecting the brain and spinal cord, potentially arising after a viral illness, including a mild common cold. This condition results from an abnormal immune response in the central nervous system and can manifest at any age, with a higher prevalence in children. If a child presents after a simple viral illness with unusual symptoms, such as confusion, changes in vision, weakness, numbness, or loss of balance, the child’s physician must be notified. Early recognition of the diagnosis and treatment will improve the outcome.

Pearls and Other Issues

ADEM is difficult to differentiate from an initial attack of multiple sclerosis (MS) based on a single clinical encounter or radiographic evidence alone in adults. Diagnosing a patient with either condition accurately is essential because the approach to treating the 2 conditions differs significantly. Though MS is characterized by repeated attacks of neurological dysfunction separated in time and space, there is a significant overlap between the 2 conditions regarding CNS symptoms and radiographic evidence. Patients with ADEM often present with a history of prodromal viral illness, fever, neck stiffness, ataxia, impaired consciousness, and encephalopathy. In contrast, patients with MS typically do not present with these complaints. Additionally, MS is more often monosymptomatic (eg, optic neuritis alone) and has a chronic, relapsing, and remitting course.[15][32]

A brain MRI may help distinguish between the 2 diseases. ADEM typically involves more extensive, bilateral, asymmetric lesions that are also higher in number than those commonly seen with MS. Brain lesions tend to be more well-defined when seen in MS, whereas ill-defined lesions are seen in ADEM. MS is more likely to be associated with brain lesions of varying ages, while ADEM typically has lesions of all approximately the same age. Lesions in the thalamus are seen more commonly in ADEM, while periventricular lesions are more common in MS.

Acute hemorrhagic encephalomyelitis (AHEM), also known as acute hemorrhagic leukoencephalitis or acute necrotizing hemorrhagic leukoencephalitis of Weston-Hurst, is a hyperacute variant of ADEM that rapidly progresses to coma and may be fatal. AHEM is triggered similarly to ADEM following exposure to an infectious organism or vaccination. Symptoms of AHEM include asymmetric multifocal neurologic deficits, meningismus, headache, and seizures.[33] A head CT or MRI of a patient with AHEM may reveal focal hemorrhagic lesions, edema, petechial and perivascular hemorrhages, vascular destruction, fibrin deposition, and neutrophilic infiltration.

Demyelinating disorders like MS, optic neuritis, MOGAD, and neuromyelitis optica spectrum disorders can overlap in presentation and convergence with ADEM; this has increasingly been recognized and considered in the diagnostic criteria for ADEM. There are multiphasic ADEM cases with an event of ADEM occurring more than 3 months following the initial ADEM diagnosis.[10]

Enhancing Healthcare Team Outcomes

The presentation, diagnosis, and management of ADEM is complex and best done with a team that includes an infectious disease expert, emergency department physician, pathologist, nurse practitioner, neurologist, psychiatrist, and intensivist. ADEM is classically seen following an illness, or less frequently, a vaccination, with a lag time ranging from a few and up to 60 days, with a mean of 26 days. Although in about 25% of affected individuals, there may not be an apparent preceding event. The onset of ADEM is acute and rapidly progressive, characterized by multifocal neurologic symptoms requiring early hospitalization. The decision to treat with an antiviral agent requires clinical judgment. Intensive care unit monitoring of these patients is required, and nurses must provide close monitoring while simultaneously providing prophylaxis against deep vein thrombosis, pressure sores, and stress ulcers. Nurses also aid in educating patients and their families, keeping the team informed about changes in patient status.

The pharmacist should provide medication reconciliation and assist with acyclovir and high-dose IV glucocorticoid therapy dosing. If a patient is not improving, the pharmacist may assist in correctly dosing and monitoring intravenous immune globulin or cyclophosphamide. In addition, the pharmacist can assist in educating the patient and family regarding medication compliance.

There are rare cases of severe hemorrhagic necrosis leading to rapid progression and death, mainly if the brainstem is affected. Only through such an interprofessional team approach can the morbidity and mortality of this disorder be reduced. The outlook of patients with ADEM is fair to good, but those who present with severe neurological deficits may have residual defects after recovery. The recovery period can take weeks or months.[26][34] 

Review Questions

• Access free multiple choice questions on this topic.
• Comment on this article.

References

1.

Essrani R, Essrani RK, Mehershahi S, Lohana AK, Sudhakaran A. Oculomotor Nerve Palsy After Influenza Vaccine in Inflammatory Bowel Disease. Cureus. 2018 Dec 21;10(12):e3759. [PMC free article: PMC6389033] [PubMed: 30820379]

2.

Nishiyama M, Nagase H, Tomioka K, Tanaka T, Yamaguchi H, Ishida Y, Toyoshima D, Fujita K, Maruyama A, Sasaki K, Oyazato Y, Nakagawa T, Takami Y, Nozu K, Nishimura N, Nakashima I, Iijima K. Clinical time course of pediatric acute disseminated encephalomyelitis. Brain Dev. 2019 Jun;41(6):531-537. [PubMed: 30833092]

3.

Krupp LB, Tardieu M, Amato MP, Banwell B, Chitnis T, Dale RC, Ghezzi A, Hintzen R, Kornberg A, Pohl D, Rostasy K, Tenembaum S, Wassmer E., International Pediatric Multiple Sclerosis Study Group. International Pediatric Multiple Sclerosis Study Group criteria for pediatric multiple sclerosis and immune-mediated central nervous system demyelinating disorders: revisions to the 2007 definitions. Mult Scler. 2013 Sep;19(10):1261-7. [PubMed: 23572237]

4.

Koelman DL, Mateen FJ. Acute disseminated encephalomyelitis: current controversies in diagnosis and outcome. J Neurol. 2015 Sep;262(9):2013-24. [PubMed: 25761377]

5.

Paolilo RB, Deiva K, Neuteboom R, Rostásy K, Lim M. Acute Disseminated Encephalomyelitis: Current Perspectives. Children (Basel). 2020 Nov 03;7(11) [PMC free article: PMC7692206] [PubMed: 33153097]

6.

Alves JM, Marques IB, Gil-Gouveia R. [Vaccination Controversies: An Adult Case of Post-Vaccinal Acute Disseminated Encephalomyelitis]. Acta Med Port. 2019 Feb 01;32(1):81-85. [PubMed: 30753808]

7.

Rossor T, Benetou C, Wright S, Duignan S, Lascelles K, Robinson R, Das K, Ciccarelli O, Wassmer E, Hemingway C, Lim M, Hacohen Y. Early predictors of epilepsy and subsequent relapse in children with acute disseminated encephalomyelitis. Mult Scler. 2020 Mar;26(3):333-342. [PubMed: 30730236]

8.

Galetta KM, Bhattacharyya S. Multiple Sclerosis and Autoimmune Neurology of the Central Nervous System. Med Clin North Am. 2019 Mar;103(2):325-336. [PubMed: 30704684]

9.

Karussis D, Petrou P. The spectrum of post-vaccination inflammatory CNS demyelinating syndromes. Autoimmun Rev. 2014 Mar;13(3):215-24. [PubMed: 24514081]

10.

Pohl D, Alper G, Van Haren K, Kornberg AJ, Lucchinetti CF, Tenembaum S, Belman AL. Acute disseminated encephalomyelitis: Updates on an inflammatory CNS syndrome. Neurology. 2016 Aug 30;87(9 Suppl 2):S38-45. [PubMed: 27572859]

11.

Absoud M, Lim MJ, Chong WK, De Goede CG, Foster K, Gunny R, Hemingway C, Jardine PE, Kneen R, Likeman M, Nischal KK, Pike MG, Sibtain NA, Whitehouse WP, Cummins C, Wassmer E., UK and Ireland Childhood CNS Inflammatory Demyelination Working Group. Paediatric acquired demyelinating syndromes: incidence, clinical and magnetic resonance imaging features. Mult Scler. 2013 Jan;19(1):76-86. [PMC free article: PMC3409874] [PubMed: 22516794]

12.

Torisu H, Okada K. Vaccination-associated acute disseminated encephalomyelitis. Vaccine. 2019 Feb 14;37(8):1126-1129. [PubMed: 30683508]

13.

Horellou P, Wang M, Keo V, Chrétien P, Serguera C, Waters P, Deiva K. Increased interleukin-6 correlates with myelin oligodendrocyte glycoprotein antibodies in pediatric monophasic demyelinating diseases and multiple sclerosis. J Neuroimmunol. 2015 Dec 15;289:1-7. [PubMed: 26616865]

14.

Brilot F, Dale RC, Selter RC, Grummel V, Kalluri SR, Aslam M, Busch V, Zhou D, Cepok S, Hemmer B. Antibodies to native myelin oligodendrocyte glycoprotein in children with inflammatory demyelinating central nervous system disease. Ann Neurol. 2009 Dec;66(6):833-42. [PubMed: 20033986]

15.

Young NP, Weinshenker BG, Parisi JE, Scheithauer B, Giannini C, Roemer SF, Thomsen KM, Mandrekar JN, Erickson BJ, Lucchinetti CF. Perivenous demyelination: association with clinically defined acute disseminated encephalomyelitis and comparison with pathologically confirmed multiple sclerosis. Brain. 2010 Feb;133(Pt 2):333-48. [PMC free article: PMC2822631] [PubMed: 20129932]

16.

Ketelslegers IA, Visser IE, Neuteboom RF, Boon M, Catsman-Berrevoets CE, Hintzen RQ. Disease course and outcome of acute disseminated encephalomyelitis is more severe in adults than in children. Mult Scler. 2011 Apr;17(4):441-8. [PubMed: 21148017]

17.

Li K, Li M, Wen L, Wang Q, Ding X, Wang J. Clinical Presentation and Outcomes of Acute Disseminated Encephalomyelitis in Adults Worldwide: Systematic Review and Meta-Analysis. Front Immunol. 2022;13:870867. [PMC free article: PMC9218070] [PubMed: 35757742]

18.

Kawanaka Y, Ando K, Ishikura R, Katsuura T, Wakata Y, Kodama H, Takaki H, Takada Y, Ono J, Yamakado K. Delayed appearance of transient hyperintensity foci on T1-weighted magnetic resonance imaging in acute disseminated encephalomyelitis. Jpn J Radiol. 2019 Apr;37(4):277-282. [PubMed: 30671706]

19.

Anand KS, Agrawal AK, Garg J, Dhamija RK, Mahajan RK. Spectrum of neurological complications in chikungunya fever: experience at a tertiary care centre and review of literature. Trop Doct. 2019 Apr;49(2):79-84. [PubMed: 30678544]

20.

Codjia P, Ayrignac X, Carra-Dalliere C, Cohen M, Charif M, Lippi A, Collongues N, Corti L, De Seze J, Lebrun C, Vukusic S, Durand-Dubief F, Labauge P., SFSEP and OFSEP. Multiple sclerosis with atypical MRI presentation: Results of a nationwide multicenter study in 57 consecutive cases. Mult Scler Relat Disord. 2019 Feb;28:109-116. [PubMed: 30592992]

21.

Ketelslegers IA, Neuteboom RF, Boon M, Catsman-Berrevoets CE, Hintzen RQ., Dutch Pediatric MS Study Group. A comparison of MRI criteria for diagnosing pediatric ADEM and MS. Neurology. 2010 May 04;74(18):1412-5. [PubMed: 20335562]

22.

Armangue T, Olivé-Cirera G, Martínez-Hernandez E, Sepulveda M, Ruiz-Garcia R, Muñoz-Batista M, Ariño H, González-Álvarez V, Felipe-Rucián A, Jesús Martínez-González M, Cantarín-Extremera V, Concepción Miranda-Herrero M, Monge-Galindo L, Tomás-Vila M, Miravet E, Málaga I, Arrambide G, Auger C, Tintoré M, Montalban X, Vanderver A, Graus F, Saiz A, Dalmau J., Spanish Pediatric anti-MOG Study Group. Associations of paediatric demyelinating and encephalitic syndromes with myelin oligodendrocyte glycoprotein antibodies: a multicentre observational study. Lancet Neurol. 2020 Mar;19(3):234-246. [PubMed: 32057303]

23.

Huda S, Whittam D, Bhojak M, Chamberlain J, Noonan C, Jacob A. Neuromyelitis optica spectrum disorders. Clin Med (Lond). 2019 Mar;19(2):169-176. [PMC free article: PMC6454358] [PubMed: 30872305]

24.

Cole J, Evans E, Mwangi M, Mar S. Acute Disseminated Encephalomyelitis in Children: An Updated Review Based on Current Diagnostic Criteria. Pediatr Neurol. 2019 Nov;100:26-34. [PubMed: 31371120]

25.

Pohl D, Tenembaum S. Treatment of acute disseminated encephalomyelitis. Curr Treat Options Neurol. 2012 Jun;14(3):264-75. [PubMed: 22476745]

26.

Bhatt P, Bray L, Raju S, Dapaah-Siakwan F, Patel A, Chaudhari R, Donda K, Bhatt NS, Dave M, Linga VG, Lekshminarayanan A, Patel SV, Billimoria ZC, Zuckerman S, Yagnik P, Singh D. Temporal Trends of Pediatric Hospitalizations with Acute Disseminated Encephalomyelitis in the United States: An Analysis from 2006 to 2014 using National Inpatient Sample. J Pediatr. 2019 Mar;206:26-32.e1. [PubMed: 30528761]

27.

Yae Y, Kawano G, Yokochi T, Imagi T, Akita Y, Ohbu K, Matsuishi T. Fulminant acute disseminated encephalomyelitis in children. Brain Dev. 2019 Apr;41(4):373-377. [PubMed: 30522797]

28.

Ketelslegers IA, Van Pelt DE, Bryde S, Neuteboom RF, Catsman-Berrevoets CE, Hamann D, Hintzen RQ. Anti-MOG antibodies plead against MS diagnosis in an Acquired Demyelinating Syndromes cohort. Mult Scler. 2015 Oct;21(12):1513-20. [PubMed: 25662345]

29.

Absoud M, Parslow RC, Wassmer E, Hemingway C, Duncan HP, Cummins C, Lim MJ., UK & Ireland Childhood CNS Inflammatory Demyelination Working Group and the the Paediatric Intensive Care Audit Network. Severe acute disseminated encephalomyelitis: a paediatric intensive care population-based study. Mult Scler. 2011 Oct;17(10):1258-61. [PubMed: 20876155]

30.

Deiva K, Cobo-Calvo A, Maurey H, De Chalus A, Yazbeck E, Husson B, Vukusic S, Serguerra C, Horellou P, Marignier R., Kidbiosep Cohort. Risk factors for academic difficulties in children with myelin oligodendrocyte glycoprotein antibody-associated acute demyelinating syndromes. Dev Med Child Neurol. 2020 Sep;62(9):1075-1081. [PubMed: 32567093]

31.

Javed A, Khan O. Acute disseminated encephalomyelitis. Handb Clin Neurol. 2014;123:705-17. [PMC free article: PMC7151857] [PubMed: 25015513]

32.

VAN BOGAERT L. Post-infectious encephalomyelitis and multiple sclerosis; the significance of perivenous encephalomyelitis. J Neuropathol Exp Neurol. 1950 Jul;9(3):219-49. [PubMed: 15437201]

33.

Mader I, Wolff M, Niemann G, Küker W. Acute haemorrhagic encephalomyelitis (AHEM): MRI findings. Neuropediatrics. 2004 Apr;35(2):143-6. [PubMed: 15127316]

34.

Ramanathan S, Mohammad S, Tantsis E, Nguyen TK, Merheb V, Fung VSC, White OB, Broadley S, Lechner-Scott J, Vucic S, Henderson APD, Barnett MH, Reddel SW, Brilot F, Dale RC., Australasian and New Zealand MOG Study Group. Clinical course, therapeutic responses and outcomes in relapsing MOG antibody-associated demyelination. J Neurol Neurosurg Psychiatry. 2018 Feb;89(2):127-137. [PMC free article: PMC5800335] [PubMed: 29142145]

Disclosure: Arayamparambil Anilkumar declares no relevant financial relationships with ineligible companies.

Disclosure: Lisa Foris declares no relevant financial relationships with ineligible companies.

Disclosure: Prasanna Tadi declares no relevant financial relationships with ineligible companies.